Diagnóstico y tratamiento de los pacientes con ANOCA Consenso SEC-Asociación de Cardiología Clínica/ SEC-Asociación de Cardiología Intervencionista/ SEC-Asociación de Cardiopatía Isquémica y Cuidados Agudos Cardiovasculares/SEC-Asociación de Imagen Cardiaca

  1. Carlos Escobar 1
  2. Josep Gómez Lara 2
  3. Javier Escaned 3
  4. Antoni Carol Ruiz 4
  5. Enrique Gutiérrez Ibañes 5
  6. Leticia Fernández Friera 6
  7. Sergio Raposeiras Roubín 7
  8. Joaquín Alonso Martín 8
  9. Jaume Agüero 9
  10. Jose María Gámez 10
  11. Pablo Jorge Pérez 11
  12. Román Freixa Pamias 4
  13. Vivencio Barrios 12
  14. Ignacio Cruz González 13
  15. Amparo Martínez Monzonís 13
  16. Ana Viana Tejedor 3
  1. 1 ervicio de Cardiología, Hospital Universitario La Paz, Madrid, España
  2. 2 ervicio de Cardiología, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, España
  3. 3 Servicio de Cardiología, Hospital Universitario Clínico San Carlos, Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IDISSC), Universidad Complutense, Madrid, España
  4. 4 Servicio de Cardiología, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, España
  5. 5 Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España
  6. 6 Servicio de Cardiología, Centro Integral de Enfermedades Cardiovasculares (HM-CIEC), HM Hospitales, Facultad HM Hospitales de Ciencias de la Salud de la Universidad Camilo José Cela, Madrid, España
  7. 7 Servicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, España
  8. 8 Servicio de Cardiología, Hospital Universitario de Getafe, Universidad Europea, Getafe, Madrid, España
  9. 9 Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, España
  10. 10 Servicio de Cardiología, Hospital Universitario Son Llàtzer, Universidad de las Islas Baleares, Palma de Mallorca, España
  11. 11 Servicio de Cardiología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, España
  12. 12 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, España
  13. 13 Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), España
Mostrar afiliaciones +
Revista:
REC: Interventional Cardiology

ISSN: 2604-7276,  2604-7306

Año de publicación: 2024

Volumen: 6

Número: 2

Páginas: 106-116

Tipo: Artículo

DOI: 10.24875/RECIC.M23000422 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: REC: Interventional Cardiology

Resumen

Un número importante de aquellos pacientes en quienes se realiza coronariografía por angina o isquemia presentan en pruebas no invasivas arterias coronarias sin lesiones o con estenosis no significativas. Muchos de estos pacientes tienen isquemia miocárdica de causa no obstructiva (INOCA/ANOCA), una condición con importancia pronóstica que afecta de manera considerable la calidad de vida. La ausencia de un diagnóstico que haga posible un tratamiento médico efectivo acarrea la repetición de pruebas diagnósticas y un mayor uso de recursos sociosanitarios. Es necesaria una estrategia diagnóstica adecuada para poder realizar un tratamiento personalizado, que mejore los síntomas y la calidad de vida. En este documento de la SEC-Asociación de Cardiología Clínica, SEC-Asociación de Cardiología Intervencionista, SEC-Asociación de Cardiopatía Isquémica y Cuidados Agudos Cardiovasculares, y SEC-Asociación de Imagen Cardiaca, se establecen unos algoritmos sencillos y prácticos con el objetivo de facilitar el diagnóstico precoz y el tratamiento más adecuado de los pacientes con ANOCA.

Referencias bibliográficas

  • Meeder JG, Hartzema-Meijer MJ, Jansen TPJ, Konst RE, Damman P, Elias-Smale SE. Outpatient Management of Patients With Angina With No Obstructive Coronary Arteries:How to Come to a Proper Diagnosis and Therapy. Front Cardiovasc Med. 2021;8:716319.
  • Perera D, Berry C, Hoole SP, et al. Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease:a consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute for Health Research Partnership. Heart. 2022;109:88-95.
  • Jansen TPJ, Konst RE, Elias-Smale SE, et al. Assessing Microvascular Dysfunction in Angina With Unobstructed Coronary Arteries:JACC Review Topic of the Week. J Am Coll Cardiol. 2021;78:1471-1479.
  • Alonso JJ, Muñiz J, Gómez-Doblas JC, et al. Prevalencia de angina estable en España. Resultados del estudio OFRECE. Rev Esp Cardiol. 2015;68:691-699.
  • Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372:1291-1300.
  • Rahman H, Ryan M, Lumley M, et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation. 2019;140:1805-1816.
  • Kunadian V, Chieffo A, Camici PG, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology and Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41:3504-3520.
  • Taqueti VR. Coronary microvascular dysfunction in vasospastic angina:provocative role for the microcirculation in macrovessel disease prognosis. J Am Coll Cardiol. 2019;74:2361-2364.
  • Luu JM, Wei J, Shufelt CL, et al. Clinical Practice Variations in the Management of Ischemia With No Obstructive Coronary Artery Disease. J Am Heart Assoc. 2022;11:e022573.
  • Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-477.
  • Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina:the CorMicA trial. J Am Coll Cardiol. 2018;72(23 Pt A):2841-2855.
  • Jansen TPJ, Konst RE, de Vos A, et al. Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA:The EDIT-CMD Randomized Clinical Trial. JACC Cardiovasc Imaging. 2022;15:1473-1484.
  • Suda A, Takahashi J, Hao K, et al. Coronary Functional Abnormalities in Patients With Angina and Nonobstructive Coronary Artery Disease. J Am Coll Cardiol. 2019;74:2350-2360.
  • Kaski JC, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA, Rosano GM. Cardiac syndrome X:clinical characteristics and left ven-tricular function:long-term follow-up study. J Am Coll Cardiol. 1995;25:807-814.
  • Sharaf B, Wood T, Shaw L, et al. Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease:findings from the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation (WISE) angiographic core laboratory. Am Heart J. 2013;166:134-141.
  • Radico F, Zimarino M, Fulgenzi F, et al. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease:a systematic review and meta-analysis. Eur Heart J. 2018;39:2135-2146.
  • Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia:results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55:2825-2832.
  • Patel S, Fung M, Liang Z, Butalia S, Anderson TJ. Temporal Trends of the Prevalence of Angina With No Obstructive Coronary Artery Disease (ANOCA). Can J Cardiol. 2023;39:63-70.
  • Mejia-Renteria H, Travieso A, Matías-Guiu JA, et al. Coronary microvascular dysfunction is associated with impaired cognitive function:the Cerebral-Coronary Connection study (C3 study). Eur Heart J. 2023;44:113-125.
  • Boerhout CKM, de Waard GA, Lee JM, et al. Prognostic value of structural and functional coronary microvascular dysfunction in patients with non-obstructive coronary artery disease;from the multicentre international ILIAS registry. EuroIntervention. 2022;18:719-728.
  • Grigorian-Shamagian L, Oteo JF, Gutiérrez-Barrios A, et al. Endothelial dysfunction in patients with angina and non-obstructed coronary arteries is associated with an increased risk of mayor cardiovascular events. Results of the Spanish ENDOCOR registry. Int J Cardiol. 2023;370:18-25.
  • Jespersen L, Abildstrøm SZ, Hvelplund A, Prescott E. Persistent angina:highly prevalent and associated with long-term anxiety, depression, low physical functioning, and quality of life in stable angina pectoris. Clin Res Cardiol. 2013;102:571-581.
  • Schumann CL, Mathew RC, Dean JL, et al. Functional and Economic Impact of INOCA and Influence of Coronary Microvascular Dysfunction. JACC Cardiovasc Imaging. 2021;14:1369-1379.
  • Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1-6.
  • Ong P, Camici PG, Beltrame JF, et al.;Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16-20.
  • Kobayashi Y, Fearon WF, Honda Y, et al. Effect of Sex Differences on Invasive Measures of Coronary Microvascular Dysfunction in Patients With Angina in the Absence of Obstructive Coronary Artery Disease. JACC Cardiovasc Interv. 2015;8:1433-1441.
  • Chung JH, Lee KE, Lee JM, et al. Effect of Sex Difference of Coronary Microvascular Dysfunction on Long-Term Outcomes in Deferred Lesions. JACC Cardiovasc Interv. 2020;13:1669-1679.
  • Nardone M, McCarthy M, Ardern CI, et al. Concurrently Low Coronary Flow Reserve and Low Index of Microvascular Resistance Are Associated With Elevated Resting Coronary Flow in Patients With Chest Pain and Nonobstructive Coronary Arteries. Circ Cardiovasc Interv. 2022;15:e011323.
  • Rahman H, Demir OM, Khan F, et al. Physiological Stratification of Patients With Angina Due to Coronary Microvascular Dysfunction. J Am Coll Cardiol. 2020;75:2538-2549.
  • Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38:2565-2568.
  • Ang DTY, Berry C. What an Interventionalist Needs to Know About INOCA. Interv Cardiol. 2021;16:e32.
  • Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011;124:1774-1782.
  • Matsumoto T, Saito Y, Saito K, et al. Relation Between Cancer and Vasospastic Angina. Adv Ther. 2021;38:4344-4353.
  • Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology &Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. EuroIntervention. 2021;16:1049-1069.
  • Hokimoto S, Kaikita K, Yasuda S, et al. JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction. Circ J. 2023;87:879-936.
  • Lee SH, Shin D, Lee JM, et al. Clinical Relevance of Ischemia with Nonobstructive Coronary Arteries According to Coronary Microvascular Dysfunction. J Am Heart Assoc. 2022;11:e025171.
  • Ziadi MC, Dekemp RA, Williams KA, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol. 2011;58;740-748.
  • Driessen RS, Raijmakers PG, Stuijfzand WJ, Knaapen P. Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging. 2017;33:1021-1031.
  • Michelsen MM, Mygind ND, Pena A, et al. Transthoracic Doppler echocardiography compared with positron emission tomography for assessment of coronary microvascular dysfunction:the iPOWER study. Int J Cardiol. 2017;228:435-443.
  • Vogel R, Indermühle A, Reinhardt J, et al. The quantification of absolute myocardial perfusion in humans by contrast echocardiography:algorithm and validation. J Am Coll Cardiol. 2005;45:754-762.
  • Thomson LE, Wei J, Agarwal M, et al. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute–sponsored study from the Women's Ischemia Syndrome Evaluation. Circ Cardiovasc Imaging. 2015;8:e002481.
  • Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med. 2002;346:1948-1953.
  • Kotecha T, Martinez-Naharro A, Boldrini M, et al. Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction:Validation Against Invasive Coronary Physiology. JACC Cardiovasc Imaging. 2019;12:1958-1969.
  • Zhou W, Lee JCY, Leung ST, et al. Long-Term Prognosis of Patients With Coronary Microvascular Disease Using Stress Perfusion Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2021;14:602-611.
  • Sammut EC, Villa ADM, Di Giovine G, et al. Prognostic Value of Quantitative Stress Perfusion Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2018;11:686-694.
  • Rahman H, Scannell CM, Demir OM, et al. High-Resolution Cardiac Magnetic Resonance Imaging Techniques for the Identification of Coronary Microvascular Dysfunction. JACC Cardiovasc Imaging. 2021;14:978-986.
  • Gutiérrez E, Gómez-Lara J, Escaned J, et al. Assessment of the endothelial function and spasm provocation test performed by intracoronary infusion of acetylcholine. Technical report from the ACI-SEC. REC Interv Cardiol. 2021;3:286-296.
  • Montone RA, Rinaldi R, Del Buono MG, et al. Safety and prognostic relevance of acetylcholine testing in patients with stable myocardial ischaemia or myocardial infarction and non-obstructive coronary arteries. EuroIntervention. 2022;18:e666-e676.
  • Rivero F, Gutiérrez-Barrios A, Gomez-Lara J, et al. Coronary microvascular dysfunction assessed by continuous intracoronary thermodilution:A comparative study with index of microvascular resistance. Int J Cardiol. 2021;333:1-7.
  • de Vos A, Jansen TPJ, van't Veer M, et al. Microvascular Resistance Reserve to Assess Microvascular Dysfunction in ANOCA Patients. JACC Cardiovasc Interv. 2023;16:470-481.
  • Beltrame JF, Tavella R, Jones D, Zeitz C. Management of ischaemia with non-obstructive coronary arteries (INOCA). BMJ. 2021;375:e060602.
  • Mehta PK, Huang J, Levit RD, Malas W, Waheed N, Bairey Merz CN. Ischemia and no obstructive coronary arteries (INOCA):A narrative review. Atherosclerosis. 2022;363:8-21.
  • Seitz A, Martínez Pereyra V, Sechtem U, Ong P. Update on coronary artery spasm 2022 –A narrative review. Int J Cardiol. 2022;359:1-6.
  • Abouelnour A, Gori T. Vasomotor Dysfunction in Patients with Ischemia and Non-Obstructive Coronary Artery Disease:Current Diagnostic and Therapeutic Strategies. Biomedicines. 2021;9:1774.
  • Ong P, Athanasiadis A, Sechtem U. Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction. Cardiovasc Drugs Ther. 2016;30:351-356.
  • Picard F, Sayah N, Spagnoli V, Adjedj J, Varenne O. Vasospastic angina:A literature review of current evidence. Arch Cardiovasc Dis. 2019;112:44-55.
  • Choi BG, Jeon SY, Rha SW, et al. Impact of Renin-Angiotensin System Inhibitors on Long-Term Clinical Outcomes of Patients With Coronary Artery Spasm. J Am Heart Assoc. 2016;5:e003217.
  • Erdamar H, Sen N, Tavil Y, et al. The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis. 2009;20:238-244.
  • Matsuda Y, Akita H, Terashima M, et al. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J. 2000;140:753-759.
  • Rambarat CA, Elgendy IY, Handberg EM, et al. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction:Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study. Int J Cardiol. 2019;276:8-13.
  • Shin ES, Lee JH, Yoo SY, et al. A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina. Heart. 2014;100:1531-1536.
  • Morrow AJ, Ford TJ, Mangion K, et al. Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial. Am Heart J. 2020;229:70-80.
Fuente de los datos: Dialnet